Licks Attorneys | Brazil | 27 Sep 2023
The Brazilian Secretariat for Economic Reforms of the current Ministry of Finance (SRE) released, this past week, the Regulatory Impact Analysis…
Taylor Wessing | Germany | 20 Sep 2023
The decision of the Higher Regional Court of Brandenburg (Oberlandesgericht Brandenburg - OLG Brandenburg) of 6 June 2023 (Ref…
Lexology PRO | United Kingdom | 19 Sep 2023
The UK’s antitrust authority rightly fined Auden McKenzie and Actavis UK for inflating the price of hydrocortisone by over 10,000% but was wrong to sanction another company as part of its decision, the Competition Appeal Tribunal has ruled.
Lexology PRO | Australia, Brazil | 14 Sep 2023
Drugmaker Boehringer Ingelheim has struck a settlement deal with Brazil’s competition watchdog, agreeing to pay a €4.35 million fine to end a probe into its role in a nearly three-decade-long conspiracy.
Lexology PRO | Australia, Canada, European Union, etc. | 14 Sep 2023
A look at the results of the ECB’s second climate stress test, a checklist for business licensing requirements and videos on how technology is transforming gambling regulation – plus other top content from Lexology PRO.
Licks Attorneys | Brazil | 22 Aug 2023
Recently, the Brazilian Antitrust Authority (Administrative Council for Economic Defense - CADE) decided to dismiss a complaint filed by Apsen…
K&S Partners | India | 2 Aug 2023
In Boehringer Ingelheim International GMBH v The Controller of Patents, the Delhi High Court ruled that a divisional application with new claims based on disclosures in the specification of the parent application cannot be allowed. The Court examined how to ascertain "plurality of invention" and whether a divisional application can be filed for claims when such claims were not a part of the......
K&S Partners | India | 26 Jul 2023
In Novartis AG v Controller of Patents and Designs, the Delhi High Court dealt yet again with the validity of divisional applications considering the issue of plurality of distinct inventions. Objections had been filed against certain compounds in Novartis AG's divisional application on the grounds that they lacked unity of invention in the parent application. The Court, however, found that......
Dacheng Shanghai | China | 6 Jul 2023
Lexology PRO | China | 31 May 2023
China’s competition authority has for the first time ever sanctioned a company for cartel conduct and abuse of dominance in a single case – slapping an active pharmaceutical ingredient supplier with a €37.7 million penalty.